

COUNSELLORS AT LAW 28 STATE STREET

BOSTON, MASSACHUSETTS 02109-1784 TELEPHONE (617) 227-7400 FAX (617) 742-4214 lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI RALPH A: LOREN GIULIO A. DeCONTI JR ANN LAMPORT HAMMITTE ELIZABETH A, HANLEY AMY BAKER MANDRAGDURAS ANTHONY A LAURENTANO KEVIN J. CANNING JANE E. REMILLARD DeANN FORAN SMITH PETER C. LAURO DEBRA J. MILASINCIC, Ph.D. DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER MEGAN E. WILLIAMS, Ph.D.

LISA M. DIROCCO HATHAWAY P. RUSSELL * MARIA LACCOTRIPE ZACHARAKIS, Ph.D. MERIDETH C. ARNOLD DANIELLE L. HERRITT **ELUHOON LEE ***

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL JEREMIAH LYNCH WILLIAM A. SCOFIELD, JR. SIBLEY P. REPPERT JEANNE M. DIGIORGIO CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS THEODORE R. WEST CYNTHIA M. SOROOS PETER W. DINI, Ph.D. JONATHAN M. SPARKS, Ph.D.

TECHNICAL SPECIALISTS CATHERINE M. BISHOP JACOB G. WEINTRAUB CRISTIN E. HOWLEY, Ph.D. JILL ANN MELLO, Ph.D. DEBORAH L. NAGLE, Ph.D. ANNE JACQUELINE NOWAK, Ph.D. ANDRINA WILLIAMS ZINK

July 8, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Re:

U.S. Patent Application No.: 10/010942

TECH CENTER 1600/2900 For: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID

PEPTIDE

Inventors: Basi, Guriq et al. Filed: December 6, 2001 Our Ref. No.: ELN-002

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Supplemental Information Disclosure Statement;
- 2. PTO Form 1449:
- 3. Copies of references cited in PTO Form 1449 (7);
- A copy of the International Search Report; and 4.
- 5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22813-1450 on: Qebra/1. Milasino

Registration No. 46,931

Respectfully submitted

Debra. Milasincic, Esq. Registration No. 46,931 Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Basi, Guriq et al.

Serial No.: 10/010942

Filed: December 6, 2001

For: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE

Attorney Docket No.: ELN-002

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Group Art Unit: 1645

Examiner: Not Yet Assigned

RECEIVED
TECH CENTER 1600/2900

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

July 8, 2003

Date of Signature and of Mail Deposit

By: Debra J. Milasincic, Esq.

Reg. No. 46,931

Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed April 17, 2003 during the prosecution of PCT/US01/46587 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

Serial Number: 10/010942 Page -2- Group Art Unit: 1645

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application for the first time not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account

No. 12-0080.

Respectfully submitted LAHIVE & COCKEIN

LIMINI

Debra/J. Milasincic, Esq. Registration No. 46,931 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: July 8, 2003

AEM/DJM/CEH/krj

Enclosures

Sheet 1 of APPLICANT FACSIMILE OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY DOCKET NO **ELN-002** 10/010942 🤣 LIST OF PUBLICATIONS CITED BY APPLICANT APPLICANT JUL 1 1 2003 (Use several sheets if necessary) Basi, Guriq et al. GROUP 1645 December 6, 2001 **U.S. PATENT DOCUMENTS** FILING DATE IF APPROPRIATE EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER DATE CLASS SUBCLASS COUNTRY **TRANSLATION**

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Japan

WO

WO

WO

WO

06/95

04/00

05/00

11/02

11/02

∕B1

B2

∙B3

B4

B5

JP 7-165799

WO 00/23082 A1

WO 00/72880 A2,A3

WO 02/088306 A2

WO 02/088307 A2

YES

Abstract Only NO

В	36	Bard, F. <i>et al.</i> "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> 6(8):916-919 (Aug 2000).
В	37	Kettleborough, C.A. <i>et al.</i> "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> 4(7):773-783 (1991).
-		

Examiner		Date Considered
*EXAMINER:	Initial if reference considered, whether or n	ot citation is in conformance with MPEP 609; Draw line through citation
	if not in conformance and not considered.	Include copy of this form with next communication to applicant.